Neogenomics Inc is a leading provider of cancer-focused genetic testing and diagnostic services
The company specializes in developing advanced technologies that enhance the accuracy of cancer diagnosis and treatment planning. Through its comprehensive suite of laboratory services, Neogenomics aids healthcare providers by offering insights into genetic markers associated with various cancers, enabling personalized medicine approaches. In addition to its testing services, Neogenomics is dedicated to research and development, striving to improve and innovate methodologies that contribute to better patient outcomes in oncology.
NeoGenomics stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th. It has soared by more than 20% from its lowest point this week.
Shares of International Flavors & Fragrances Inc. (NYSEIFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share.
NeoGenomics shines in Q4 2023 with an EPS turnaround to $0.03, beating estimates. Sales reach $155.55 million. CEO Chris Smith anticipates strong growth, guiding a positive fiscal 2024 outlook with an EPS forecast of $0.04.
Shares of NeoGenomics, Inc. (NASDAQNEO) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS guidance above estimates.
